Niki BioSolutions, Inc. (NIKI) AI Stock Analysis

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing therapeutics for oncology and infectious diseases. Its pipeline includes SACT-1, a repurposed drug candidate in Phase 1 clinical testing for neuroblastoma and other cancers, and ALS-4, in Phase 1 trials for bacterial infections such as staphylococcus aureus. The company also develops preclinical candidates including SACT-COV19 for coronavirus disease, SACT-2, SACT-3, ALS-1 for bacterial infections including MRSA, and ALS-2/3 for gram+ve bacterial infections. Headquartered in Princeton, New Jersey, the company has 1 employee and operates as a subsidiary of Jurchen Investment Corporation.

Niki BioSolutions generated annual revenue of $535,166 in FY2019, growing to $911,509 in FY2020 and peaking at $1.5M in FY2021 with 69.2% growth. Revenue subsequently fell 16.0% to $1.3M in FY2022 and dropped 66.7% to $431,378 in FY2023, yielding a 5-year revenue CAGR from FY2018 to FY2023 of 2.4%. Net income was -$18.7M in FY2019, $7.1M in FY2020, -$25.0M in FY2021, -$9.8M in FY2022, and -$2.8M in FY2023. Gross margin was 2.4% in FY2023, while operating margin was -2457.5%. In the trailing twelve months ending December 31, 2025, revenue was $0, operating margin was 0.0%, and EPS was -$2.90.

As of December 31, 2025, Niki BioSolutions held $3.5M in cash and short-term investments against total debt of $3.4M, resulting in net cash of $9,963. The company reported total assets of $18.7M, shareholders' equity of $23.2M, and a debt-to-equity ratio of 0.15. Its current ratio stood at 0.78. In FY2023, operating cash flow was -$7.7M and free cash flow was -$7.7M, while R&D expense was $5.2M. Over the five-year period through FY2025, share count increased 145.0%.

At a last close of $2.03 on October 16, 2026, Niki BioSolutions had a market cap of $6.3M and an enterprise value of $5.6M. The stock traded at a price-to-sales ratio of 23.4x, which is elevated compared to 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio stood at 0.2x, while EV to revenue was 31.2x. Over the past year, NIKI fell 86.6%, lagging the 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 99.2% versus an 83.0% return for the benchmark.

There are currently no Wall Street analyst ratings, consensus price targets, or earnings estimates available for Niki BioSolutions, Inc. The company also has no scheduled next earnings date or published earnings track record metrics. NIKI shares closed at $2.03 on October 16, 2026, positioned between a 52-week low of $1.94 and a 52-week high of $17.20, and trading 75.1% below its 200-day moving average.

This page is an AI-written research summary of Niki BioSolutions, Inc. (NIKI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NIKI income statement, NIKI balance sheet, NIKI key metrics, NIKI chart. See the NIKI stock overview for the latest quote and news.